Vitamiinit ja mineraalit

Screenshot_20240122_104115_Facebook.webp


pubmed.ncbi.nlm.nih.gov

Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies - PubMed

Higher omega-3 PUFA levels are associated with lower risks of total and ischemic stroke but have no association with hemorrhagic stroke.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov
 

Whereas our meta-analysis found significant positive impacts on CVD outcomes,1,2 the paper by O’Keefe and colleagues3 reports reductions in deaths from CVD, cancer, and other causes; these findings support the benefits of omega-3 despite a potential increased risk of AF, notwithstanding the absence of an increased ischemic stroke risk. The recent Mayo Clinic Proceedings study provided additional evidence on the implementation of omega-3 fatty acids in a healthy diet in the prevention of CVD and other disease outcomes; thus, the inclusion of DHA (and combined EPA and DHA) in disease prevention strategies can definitely still be recommended. The recent UK Biobank study strengthens the concept that DHA, a marine-sourced omega-3 consumed along with EPA, mostly from fatty fish or omega-3 supplements, is beneficial for overall general and cardiovascular health. There is increasing evidence that higher doses of omega-3 are safe and may reduce adverse CVD events in patients with high risk of CVD as well as potentially non-CVD, including cancer mortality.reports reductions in deaths from CVD, cancer, and other causes; these findings support the benefits of omega-3 despite a potential increased risk of AF, notwithstanding the absence of an increased ischemic stroke risk. The recent Mayo Clinic Proceedings study provided additional evidence on the implementation of omega-3 fatty acids in a healthy diet in the prevention of CVD and other disease outcomes; thus, the inclusion of DHA (and combined EPA and DHA) in disease prevention strategies can definitely still be recommended. The recent UK Biobank study strengthens the concept that DHA, a marine-sourced omega-3 consumed along with EPA, mostly from fatty fish or omega-3 supplements, is beneficial for overall general and cardiovascular health. There is increasing evidence that higher doses of omega-3 are safe and may reduce adverse CVD events in patients with high risk of CVD as well as potentially non-CVD, including cancer mortality.Whereas our metaanalysis found significant positive impacts on CVD outcomes,1,2the paper by O’Keefe and colleagues3
-

Significant concerns have recently been raised about the effects of omega-3 fatty acids to increase the risk of atrial fibrillation (AF), but little or no increase has been seen with lower doses (≤1 g/d).9,10 Whereas the presence of a dose-effect relationship indicates the effect is real, there is considerable uncertainty about its magnitude. Of 91 interventional trials with CVD outcomes with length of more than 1 year identified in the literature search of Abdelhamid et al,4 Bae et al11 found just 8 studies that included AF as an outcome. It is possible that studies with a small or null observed effect may have been omitted from the meta-analysis because of a selective reporting bias that would tend to exaggerate the magnitude of the risk. In addition, Samuel and Nattel12 observed the presence of an informative censoring bias because EPA and DHA reduce the risk of multiple CVD and mortality risks: patients in the treated groups of EPA/DHA trials would thus have more time and opportunity to develop AF than controls. One of the greatest concerns among patients with AF is the increased risk of stroke. Although the study of O’Keefe et al3 does not address the risk of stroke, the same group13 has recently found that higher omega-3 levels are associated with a lower risk of total and ischemic stroke.

Bringing the Potential Benefits of Omega-3 to a Higher Level https://www.mayoclinicproceedings.org/…/S0025-6196…/fulltext
 
Huomasin just että vahvat kalaöljykapselit haittaa itsellä unta jos otan ennen nukkumaanmenoa. Redditistä löytyi useampia vastaavia kokemuksia.
 
Nykyään otan
Dona sanoi:
Huomasin just että vahvat kalaöljykapselit haittaa itsellä unta jos otan ennen nukkumaanmenoa. Redditistä löytyi useampia vastaavia kokemuksia.
Click to expand...

Mielenkiintoista. Mikähän tossa mekanismi? Ite ottanu yleensä juurikin illalla.
 
Dona sanoi:
Joku selitti näin redditissä

katso liitettä 263112
Click to expand...

Ok. Kuulostaa melko huteralta selitykseltä. Nukahtamiseen en itse ole huomannut mitään negaa esim. Ibuprofeenista mikä varmasti kovempi anti-inflammatoori kuin kalaöljy. Enkä myöskään kalaöljystä. Ottanut vuosikymmeniä aina ennen nukkumaanmenoa välttääkseni kalaröyhtäykset. En tiedä sitten unen laadusta. Kokeilen ottaa aamulla.

Tällä hetkellä menee;
3 kapselia Puhdas+ kalaöljy
1 kapseli Vitamar-1000

Yhteensä
Omega3: 3060 mg
EPA 1680 mg
DHA 1020
 
mikasa90 sanoi:
Mulla vatsa reagoi huonolla tavalla kalaöljyyn. Nyt en oo varmaan 2-4kk käyttäny. Voisin pienellä annoksella ruveta käyttää taas.
Click to expand...

Ootko kuinka montaa eri valmistetta kokeillu? Kaikissa sama homma?

Meinaan onko väliä onko etyyliesteröity vai triglyseridi. Triglyt aina paljon kalliimpia.
 
Force sanoi:
Ootko kuinka montaa eri valmistetta kokeillu? Kaikissa sama homma?

Meinaan onko väliä onko etyyliesteröity vai triglyseridi. Triglyt aina paljon kalliimpia.
Click to expand...
Yleensä tota. Lysi omega 3 sitruuna.
Nestemäistä aina. https://www.yliopistonapteekki.fi/lysi-omega-3-lemon-kalaoljy-240-ml-16148?utm_source=google&utm_medium=cpc&utm_campaign= - (20330682372)&utm_content= - (156538197728)&utm_term=&gclid=Cj0KCQjwq86wBhDiARIsAJhuphmvzhUQAmX81Baq-J98YjVxXf3SBmBxza5wic2O9lrepPE3fyPDGXMaAul8EALw_wcB
 
Aikamoinen sattuma keskustelu täällä. Otin eilen illalla poikkeuksellisesti kalaöljyt juuri ennen nukkumaan menoa kun yleensä otan aamulla tai iltapäivällä viimeistään. Jäi viime yön unet 3-5 tuntiin kun heräili jatkuvasti eikä meinannut uni tulla uudelleen. Yleensä nukun sen 8h helposti.

Voi hyvinkin olla vain sattuma.
 
kysyvaan sanoi:
Aikamoinen sattuma keskustelu täällä. Otin eilen illalla poikkeuksellisesti kalaöljyt juuri ennen nukkumaan menoa kun yleensä otan aamulla tai iltapäivällä viimeistään. Jäi viime yön unet 3-5 tuntiin kun heräili jatkuvasti eikä meinannut uni tulla uudelleen. Yleensä nukun sen 8h helposti.

Voi hyvinkin olla vain sattuma.
Click to expand...

Mulla käy just noin että heräilen jatkuvasti ja on vaikea päästä syvään uneen. Kalaöljy ilmeisesti nostaa asetyylikoliinia aivoissa ja asetyylikoliini pitäisi olla alhaalla syvässä unessa.
 

Tod näk saan koko lapun jossain vaiheessa.​

Omega-3 fatty acids and human health: why strong claims remain on fragile consensus​

Giacomo Fassini, Priscila; Rezzi, Serge

Author Information
Current Opinion in Clinical Nutrition and Metabolic Care ():10.1097/MCO.0000000000001224, March 16, 2026. | DOI: 10.1097/MCO.0000000000001224
AbstractPlain Language Summary

Purpose of review​

Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) consumption remains widespread despite inconsistent reported health benefits. This review discusses multiple issues related to the efficiency of ω-3 PUFAs on human health including factors driving ω-3 PUFAs bioavailability and growing concerns about product quality.

Recent findings​

Recent clinical research reports ω-3 PUFAs benefits in various areas including cardiometabolic health, inflammation, cognitive protection, pregnancy outcomes, cancer and certain neuropsychiatric conditions. However, effects on healthy individuals and dietary recommendations need stronger clinical evidence. Heterogeneity in supplementation response involves genetic variability, microbiome, oxidative stress, diet and differences in supplementation protocols. Moreover, some of ω-3 PUFAs products are prone to significant oxidative degradation which can drastically reduce health benefits while possibly being detrimental. Yet ω-3 PUFAs oxidation status of products remains rarely reported and the effects of long-term consumption of oxidized lipids in humans still need to be established.

Summary​

Future clinical practices and research should shift toward biomarker-guided and personalized ω-3 PUFAs intervention strategies with mandatory prerequisite knowledge about product quality, e.g. dietary supplements and ω-3 PUFAs rich/fortified foods, and baseline blood-based ω-3 PUFAs nutritional status. Standardized reporting of formulation, oxidation status, and participant baseline characteristics is essential to clarify dose–response relationships and optimize therapeutic efficacy of ω-3 PUFAs.
 
Back
Ylös Bottom